Design Therapeutics Inc

For the period ended Dec 31, 2024. Filed Mar 10, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 10, 2025

DSGN$10.65-1.4%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets as of December 31, 2024 and 2023

Balance Sheets

(in thousands, except share and par value data)

	December 31,	December 31,
	2024	2023
Assets
Current assets:
Cash and cash equivalents	$22,563	$21,200
Investment securities	222,914	260,598
Prepaid expenses and other current assets	2,563	2,786
Total current assets	248,040	284,584
Property and equipment, net	1,410	1,691
Right-of-use asset, related party	2,216	2,938
Other assets	427	430
Total assets	$252,093	$289,643
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable	$2,186	$1,940
Accrued expenses and other current liabilities (including related party amounts of $800 and $716, respectively)	6,276	7,682
Total current liabilities	8,462	9,622
Operating lease liability, net, related party	1,534	2,334
Total liabilities	9,996	11,956
Commitments and contingencies (See Note 11)
Stockholders' equity:
Common stock: $0.0001 par value; 200,000,000 shares authorized, 56,754,341 and 56,473,598 shares issued and outstanding at December 31, 2024 and 2023, respectively	6	6
Additional paid-in capital	468,830	455,245
Accumulated deficit	(227,214)	(177,626)
Accumulated other comprehensive income	475	62
Total stockholders' equity	242,097	277,687
Total liabilities and stockholders' equity	$252,093	$289,643

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.